Overview

Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients

Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
open-label, multiple dose, single-group, 12 week trial in HIV-infected patients with hyperlipidemia while using lopinavir/ritonavir; both male or female subjects.
Phase:
Phase 2
Details
Lead Sponsor:
Radboud University
Collaborators:
Abbott
AstraZeneca
Treatments:
Lopinavir
Ritonavir
Rosuvastatin Calcium